<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Can ALNY&#x27;s Key Partnerships With Pharma Giants Drive Long-Term Growth? — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Can ALNY&#x27;s Key Partnerships With Pharma Giants Drive Long-Term Growth?</h2>
    <div class="badge">2025-09-08T14:15:00+00:00</div>
    <ul>
      <li>The drug generated $801.9 million in global sales in the first half of 2025, representing a staggering 89% year-over-year growth, driven by patient demand.</li>
<li>Alnylam Pharmaceuticals ALNY currently markets four approved drugs — Onpattro, Givlaari, Oxlumo, and Amvuttra — which together generated $1.14 billion in net product revenues, representing a 47% year-over-year increase i</li>
<li>Building on positive phase II KARDIA data, Alnylam and Roche plan to launch the global phase III ZENITH CV outcomes study by late 2025, enrolling about 11,000 high-risk hypertension patients.</li>
<li>The agreement regarding cemdisiran underwent a modification last year.</li>
<li>Alnylam, in collaboration with Roche, is developing investigational RNAi therapy zilebesiran in a mid-stage study (KARDIA-3) to treat hypertension.</li>
<li>The study will test whether twice-yearly 300 mg doses of zilebesiran can reduce the risk of major adverse cardiovascular events compared to placebo.</li>
<li>Recently, the companies reported encouraging Cohort A results, where a single 300 mg dose of zilebesiran achieved clinically meaningful and sustained reductions in office and ambulatory systolic blood pressure, as well a</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Can ALNY&amp;#x27;s Key Partnerships With Pharma Giants Drive Long-Term Growth?\n• The drug generated $801.9 million in global sales in the first half of 2025, representing a staggering 89% year-over-year growth, driven by patient demand.\n• Alnylam Pharmaceuticals ALNY currently markets four approved drugs — Onpattro, Givlaari, Oxlumo, and Amvuttra — which together generated $1.14 billion in net product revenues, representing a 47% year-over-year increase i\n• Building on positive phase II KARDIA data, Alnylam and Roche plan to launch the global phase III ZENITH CV outcomes study by late 2025, enrolling about 11,000 high-risk hypertension patients.\n• The agreement regarding cemdisiran underwent a modification last year.\n• Alnylam, in collaboration with Roche, is developing investigational RNAi therapy zilebesiran in a mid-stage study (KARDIA-3) to treat hypertension.\n• The study will test whether twice-yearly 300 mg doses of zilebesiran can reduce the risk of major adverse cardiovascular events compared to placebo.\n• Recently, the companies reported encouraging Cohort A results, where a single 300 mg dose of zilebesiran achieved clinically meaningful and sustained reductions in office and ambulatory systolic blood pressure, as well a" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/alnys-key-partnerships-pharma-giants-141500157.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>